Merck Sharp & Dohme (I.A.) Corp
Welcome,         Profile    Billing    Logout  
 11 Trials 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Recto, Cesar
KEYNOTE-057, NCT02625961 / 2014-004026-17: Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/)

Checkmark From KEYNOTE-057 trial in NMIBC
Jun 2021 - Jun 2021: From KEYNOTE-057 trial in NMIBC
Checkmark KEYNOTE-057 trial in NMIBC
Dec 2018 - Dec 2018: KEYNOTE-057 trial in NMIBC
Recruiting
2
320
Europe, Canada, US, RoW
Pembrolizumab, MK-3475, KEYTRUDA, Pembrolizumab/vibostolimab coformulation, MK-7684A, Favezelimab/pembrolizumab coformulation, MK-4280A
Merck Sharp & Dohme LLC, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Merck Sharp & Dohme Corp., a subsidiary of Merck &
Bladder Cancer
08/26
08/30
KEYNOTE-158, NCT02628067 / 2015-002067-41: Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/)

Dec 2023 - Dec 2023: Primary completion of P2 KEYNOTE-158 trial in advanced solid tumors
Checkmark Result from KEYNOTE-158 trial for 2L solid tumor
Sep 2022 - Sep 2022: Result from KEYNOTE-158 trial for 2L solid tumor
Checkmark ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
Mar 2021 - Mar 2021: ORR, OS and PFS data from KEYNOTE-158 trial for cervical cancer
More
Recruiting
2
1609
Europe, Canada, US, RoW
pembrolizumab, MK-3475, SCH 900475, KEYTRUDA®
Merck Sharp & Dohme LLC
Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial Cancer, Cervical Carcinoma, Cervical Cancer, Vulvar Carcinoma, Vulvar Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer (SCLC), Mesothelioma, Thyroid Carcinoma, Thyroid Cancer, Salivary Gland Carcinoma, Salivary Gland Cancer, Salivary Cancer, Parotid Gland Cancer, Advanced Solid Tumors, Colorectal Carcinoma
05/27
05/27
Arnold, Georgina
ACTRN12611000364976: Pharmacokinetics and Safety of Solid Oral Posaconazole(SCH 56592) in Subjects at High Risk for Invasive Fungal Infections

Not yet recruiting
1
160
 
Schering-Plough Pty limited, Schering-Plough Pty limited
High Risk for Invasive Fungal Infection due to: - Expected neutropenia (low white blood cell count) due to chemotherapy for Acute Myelogenous Leukaemia (AML) or Myelodysplastic Syndrome (MDS), High Risk for Invasive Fungal Infection due to: - Hematopoietic stem cell transplant (HSCT) recipients undergoing treatment for graft-versus-host disease (GVHD)
 
 

Download Options